1. Home
  2. LU vs ABUS Comparison

LU vs ABUS Comparison

Compare LU & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lufax Holding Ltd each representing two (2)

LU

Lufax Holding Ltd each representing two (2)

SELL

Current Price

$7.17

Market Cap

715.9M

Sector

Finance

ML Signal

SELL

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

SELL

Current Price

$4.16

Market Cap

836.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LU
ABUS
Founded
2005
2005
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
715.9M
836.0M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
LU
ABUS
Price
$7.17
$4.16
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $23.54
N/A
AVG Volume (30 Days)
555.1K
★ 2.2M
Earning Date
10-27-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
N/A
★ 1.13
Revenue
N/A
★ $14,083,000.00
Revenue This Year
N/A
$1,208.75
Revenue Next Year
$1.80
N/A
P/E Ratio
★ N/A
$3.62
Revenue Growth
N/A
★ 128.21
52 Week Low
$0.83
$3.50
52 Week High
$9.60
$5.45

Technical Indicators

Market Signals
Indicator
LU
ABUS
Relative Strength Index (RSI) 61.15 47.84
Support Level $1.38 $3.59
Resistance Level $9.31 $4.52
Average True Range (ATR) 0.61 0.20
MACD -0.30 0.03
Stochastic Oscillator 25.31 61.39

Price Performance

Historical Comparison
LU
ABUS

About LU Lufax Holding Ltd each representing two (2)

Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: